Showing results (41-50 of 53) with videos related to
Sort By:
Pageof 6
JCO Clinical Cancer Informatics|January 25, 2021
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal CancerWilliam H Ward, Caitlin R Meeker, Elizabeth Handorf, et al.Lancet (London, England)|September 13, 2022
Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trialSumanta Kumar Pal, Robert Uzzo, Jose Antonio Karam, et al.The Journal of Urology|February 4, 2021
Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective TrialMatthew Zibelman, Aeen M Asghar, Daniel C Parker, et al.The Oncologist|May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate CancerRavi A Madan, Marijo Bilusic, Mark N Stein, et al.Nature Communications|July 27, 2023
A phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumorsMatthew Zibelman, Alexander W MacFarlane, Kimberly Costello, et al.Journal for Immunotherapy of Cancer|October 17, 2022
Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinomaLandon C Brown, Jason Zhu, Kunal Desai, et al.Journal for Immunotherapy of Cancer|January 20, 2023
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumorsCharles M Rudin, Hardev S Pandha, Matthew Zibelman, et al.European Urology Oncology|November 14, 2018
Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-invasive Bladder Cancer: Results of a Phase 2 TrialFern Anari, John O'Neill, Woonyoung Choi, et al.Oncoimmunology|September 14, 2020
Proliferative potential and response to nivolumab in clear cell renal cell carcinoma patientsTian Zhang, Sarabjot Pabla, Felicia L Lenzo, et al.Journal for Immunotherapy of Cancer|May 11, 2018
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison, Sarabjot Pabla, Jeffrey M Conroy, et al.Pageof 6